Linifanib (ABT-869; AL-39324)

Description: Linifanib (formerly RG3635, ABT869, AL39324) is an orally bioavailable and ATP-competitive inhibitor of multiple kinases (e.g. VEGFR/PDGFR) with potential antitumor activity. It inhibits KDR, CSF-1R, Flt-1/3 and PDGFRbeta with IC50s of 4 nM, 3 nM, 3 nM/4 nM and 66 nM, respectively. Linifanib exhibits excellent anti-proliferative activity in vitro and high in vivo antitumor efficacy.

References: Mol Cancer Ther. 2006 Apr; 5(4):995-1006; Mol Cancer Ther. 2006 Apr; 5(4):1007-13; Mol Cancer Ther. 2011 Jun; 10(6):949-59.

Chemical Name: N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea

InChi Key: ACPCMBPQKQTAQY-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)27(21(24)28)14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)26-25-17/h2-11H, 1H3, (H2, 24, 28)(H3, 23, 25, 26)

SMILES Code: O=C(N)N(C1=CC=C(C2=CC=CC3=C2C(N)=NN3)C=C1)C4=CC(C)=CC=C4F